How do you approach choice of systemic chemotherapy for a young and otherwise healthy patient with HER2 negative esophogeal adenocarcinoma?

I really think that, in the US context, FOLFOX is the standard and preferred regimen. It is now the accepted regimen in US single-arm and randomized studies. Although there are differing toxicities, I would argue that cisplatin 60-80 mg/m2 (which is the dose in published regimens) represents cruel a...